Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blind Trial to Evaluate the Efficacy, Safety and Immunogenicity of MSB11022 Compared With Humira in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Next Previous
Trial Profile

A Randomized, Double-blind Trial to Evaluate the Efficacy, Safety and Immunogenicity of MSB11022 Compared With Humira in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 06 Jul 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Adalimumab (Primary)
  • Indications Plaque psoriasis
  • Focus Registrational; Therapeutic Use
  • Acronyms AURIEL-PsO
  • Sponsors EMD Serono; Merck KGaA

Most Recent Events

  • 17 Jun 2019 Results published in the British Journal of Dermatology
  • 22 May 2019 Results assessing quality of life outcomes of MSB11022 versus reference adalimumab presented at the 24th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research.
  • 03 Apr 2019 According to a Fresenius Kabi media release, the European Commission (EC) granted marketing authorization for IDACIO, an adalimumab biosimilar, for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, axial spondyloarthritis including ankylosing spondylitis, psoriatic arthritis, adult and paediatric, plaque psoriasis, adult and adolescent hidradenitis suppurativa, adult and paediatric Crohn's disease, ulcerative colitis, adult and paediatric noninfectious uveitis4.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top